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Abstract—Dysfunctions of the geniculo-striatal magnocellu-
lar (M) visual pathway and its cortical recipients have been
documented in fragile X syndrome and in FMR1 premutation
carriers. However, the mechanism of this impairment is less
clear. To elucidate this issue, we completed the measurement
of visual functions at different stages of information process-
ing: low-level mechanisms (contrast sensitivity biasing infor-
mation processing toward the M and parvocellular [P] path-
ways), primary visual cortex (motion-defined and static
Vernier threshold), and higher-level form and motion pro-
cessing (coherence thresholds). Results revealed that FMR1
premutation carriers, relative to non-carrier controls, exhib-
ited lower contrast sensitivity for M pathway-biased stimuli,
higher Vernier threshold for motion-defined stimuli, and
higher global motion coherence threshold. Although both
elevated FMR1 mRNA and reduced fragile X mental retarda-
tion protein (FMRP) levels were associated with impaired
visual functions, regression analysis indicated that FMRP
was the primary factor. In premutation carriers, a toxic gain-
of-function of elevated FMR1 mRNA has been suggested,
whereas reduced FMRP is linked to neurodevelopmental as-
pects. Here, we showed that FMRP may the primary factor
associated with visual dysfunctions. © 2012 IBRO. Published
by Elsevier Ltd. All rights reserved.
Key words: fragile X syndrome, premutation carrier, neuro-
development, vision, RNA toxicity.
Fragile X syndrome (FXS) is a prevalent form of inherited
neurodevelopmental disorders leading to intellectual dis-
ability. In the full syndrome, the fragile X mental retardation
protein (FMRP) is absent, which is a consequence of
FMR1 gene silencing. The mechanism of gene silencing is
based on the expansion of a CGG trinucleotide repeat
(Xq27.3, 200 repeats in the full syndrome) and an in-
creased methylation of the promoter region (O’Donnell and
Warren, 2002; Bear et al., 2008; Walter et al., 2009; Rous-
seau et al., 2011). FMRP is a widespread negative regu-
lator of translation, and therefore its absence leads to the
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183increased translation of several genes (De Rubeis and
Bagni, 2011).
In contrast to full FXS, in FMR1 premutation carriers
the size of the CGG expansion is between 55 and 200
repeats, which is associated with a subtle cognitive and
neuropsychiatric phenotype (Hagerman et al., 1996; Ben-
netto et al., 2001; Steyaert et al., 2003; Moorem et al.,
2004; Cornish et al., 2005, 2009; Bourgeois et al., 2009;
Boyle and Kaufmann, 2010; but see Franke et al., 1999). In
premutation carriers, there is no absolute FMR1 gene
silencing. The expression of expanded CGG triplets in
messenger RNA (mRNA) may have negative conse-
quences, resulting in premature ovarian insufficiency and
fragile X-associated tremor/ataxia syndrome (Hagerman
and Hagerman, 2004; Berman and Wilemsen, 2009;
Hunter et al., 2010). This toxic gain-of-function of excess
mRNA is complicated by the fact that there is an associa-
tion among reduced FMRP, increased FMR1 transcription,
and CGG repeat number in intermediate-length and pre-
mutation carriers (Kenneson et al., 2001), which is be-
cause of a less efficient initiation of translation (Ludwig et
al., 2011). This may also contribute to dysfunctions ob-
served in premutation carriers (Hessl et al., 2011). Lower
FMRP expression may be associated with various psychi-
atric disorders, including schizophrenia, depression, and
anxiety (Fatemi and Folsom, 2011; Qin et al., 2011).
Our aim was to study how increased FMR1 mRNA and
decreased FMRP levels contribute to visual dysfunction in
premutation carriers. Patients with FXS and premutation
carriers display visual perceptual anomalies, which are
characterized by the impairment of the precortical magno-
cellular (M) pathway and its cortical targets (Kogan et al.,
2004a,b; Farzin et al., 2008; Kéri and Benedek, 2009,
2010). Cells of the M pathway can be stimulated by low
luminance contrast, low spatial frequencies (coarse reso-
lution of objects), and rapid temporal changes. In contrast,
parvocellular (P) pathways prefer static patterns with me-
dium and high spatial frequency (fine details of objects)
and colors (Van Essen and Gallant, 1994; Nassi and Cal-
laway, 2009). After an interaction in the primary visual
cortex (V1), M pathways give an intensive afferentation to
cortical areas responsible for motion perception, detection
of spatial location, and visuomotor coordination (dorsal
occipitoparietal stream). P pathways give afferents to ven-
tral occipitotemporal regions responsible for color percep-
tion and object recognition (Van Essen and Gallant, 1994;
Nassi and Callaway, 2009).
Kogan et al. (2004a) and Zangenehpour et al. (2009)
demonstrated that the M layers of the lateral geniculate
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S. Kéri and G. Benedek / Neuroscience 206 (2012) 183–189184nucleus exhibit high FMRP expression, which suggests
that these neurons are especially vulnerable in FXS. In
accordance with these findings, we found a positive rela-
tionship between FMRP expression in lymphocytes and M
pathway/dorsal stream functions in healthy volunteers
(Kéri and Benedek, 2011). The fact that FXS patients
present visual impairments indicates that visual dysfunc-
tions in premutation carriers may be because of the re-
duced FMRP levels, rather than the increased FMR1
mRNA expression. In the present study, we directly inves-
tigated how FMR1 mRNA levels, a potential marker of
neuronal toxicity in premutation carriers, and FMRP ex-
pression contribute to visual functions.
EXPERIMENTAL PROCEDURES
Participants
We enrolled 21 men with FMR1 premutation (sons of female
remutation carriers) and 20 control volunteers (Table 1). All
articipants underwent molecular biological assessment (see Mo-
ecular biological measurements) and detailed neurological and
sychiatric examination. None of the participants exhibited signs
nd symptoms of neurological or mental disorders. General intel-
ectual functions were evaluated with the Wechsler Adult Intelli-
ence Scale-III (Wechsler, 1997). Exclusion criteria included re-
al, liver, cardiac, and endocrinological diseases, history of head
rauma, migraine, and alcohol or drug abuse. All participants gave
ritten informed consent, and the institutional ethics board ap-
roved the study.
Visual contrast sensitivity
We used the method described in our previous studies (Kéri and
Benedek, 2009, 2011). Stimuli were vertical sinusoidal luminance-
contrast gratings. The gratings used to bias information process-
ing toward the M and P pathways had different spatiotemporal
properties (M pathway—spatial frequency: 0.3 cycle/degree, tem-
poral frequency: 10 Hz; P pathway—spatial frequency: 10 cycles/
degree, temporal frequency: 1 Hz) (Fig. 1). The stimulus area was
circular (diameter: 8 degrees of visual angle, luminance: 31 cd/m2,
nitial Michelson contrast: 12%). This level was increased or de-
Table 1. Demographic and molecular characteristics
FMR1 premutation carriers
(n21)
Controls
(n20)
ge (y) 32.3 (8.6) 34.9 (10.5)
Education (y) 12.6 (3.9) 12.4 (4.4)
IQ 105.9 (11.3) 104.8 (10.5)
CGG* 110.4 (30.0) 25.3 (3.4)
FMR1* 3.6 (1.7) 1.3 (0.2)
FMRP* 68.2 (40.4) 134.2 (79.4)
Data are mean (standard deviation).
* P0.001.Fig. 1. Illustration of gratings used for coreased according to a Yes/No one-up/two-down staircase proce-
ure. Participants entered the responses by pressing one of two
eys on the computer keyboard. The staircase was finished when
he slope and SD of the last 12 trials were less than the step size.
he detection thresholds were the mean value of the last 12
eversals.
Static and motion-defined Vernier
We adopted the method of McKendrick et al. (2006). Stimuli were
two vertical bars, which were defined either by static white dots
(luminance: 100 cd/m2) against a black background (luminance:
.5 cd/m2) or by the relative motion of randomly placed dots (Fig.
2). The vertical bars were characterized by the following param-
eters: dot size (17 s arc-square pixels), horizontal and vertical
extent (10 min arc wide and 15 min arc high), and vertical offset (4
min arc). In this static condition, the dots did not move on the
screen.
In the motion-defined condition, a central circular area (diam-
eter: 1.23 degrees of visual angle) was first covered with randomly
placed dots (density: 4593 dots/°2), and therefore no bar stimuli
ppeared on the screen. The bars became visible when the back-
round dots moved upward (speed: 1.25 degrees/s), whereas the
Fig. 2. Vernier stimuli. The vertical bars were composed of white dots
against a black background. There was a horizontal displacement
between the bars.ntrast sensitivity measurements.
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(eight frame motion sequence, stimulus duration: 456 ms). Dot
density and stimulus duration were the same in the static and
motion-defined conditions.
We measured thresholds with a single-interval, forced-choice
procedure. In the test interval, stimuli were presented with a
variable degree of horizontal displacement (left or right in a ran-
domized order) between the upper and lower bars (Fig. 2). Par-
ticipants were asked to decide whether the bars were displaced or
not (they were not informed that stimuli are necessarily displaced,
and filler trials with no displacement were included). The horizon-
tal offset of the bars was reduced in the case of three consecutive
correct responses and was increased after each incorrect re-
sponse (three-down/one-up staircase converging on 79% correct
performance). Two staircases were interleaved. The initial dis-
placement of the bars was 2 min arc for the static condition and 6
min arc for the motion-defined condition. The initial staircase step
size was 20 s arc, which was halved on the first two reversals. The
staircases were completed after six reversals. The result of the
staircase was the average of the final four reversals. The mean of
the two interleaved thresholds was the final dependent measure.
Form and motion coherence
For the measurement of coherence thresholds, we used Glass
pattern stimuli (Glass, 1969; McKendrick et al., 2006). Glass
patterns consisted of dot pairs randomly placed within a circular
stimulus area (distance between dots: 9 min arc, diameter of
stimulus area: 10 degrees of visual angle, number of dots: 200).
The luminance of the dots and background were identical to that
used in the Vernier test. The pattern was concentric, which means
that dot pairs were perpendicular to the center of the image (Fig.
3). During the measurement of form coherence threshold, some
coherent dots were replaced with randomly positioned noise dots.
For example, in a 50% coherence pattern, half of the dots were
paired and positioned concentrically, whereas half of the dots
were placed randomly.
The size and luminance of the dots were the same in the form
Fig. 3. Illustration of Glass pattern stimuli used for coherence thresh-
ld measurements.and motion condition. Motion was generated similarly to the mo- ition-defined Vernier test. A percentage of randomly chosen dots
moved in the signal direction, whereas all other dots moved in
random directions (9 min arc/frame, 3 degrees/s).
We measured thresholds with a single-interval, forced-choice
procedure. Participants indicated whether the interval contained a
concentric structure (form coherence task) or downward motion
(motion coherence task). As in the case of the Vernier task, we
used a three-down/one-up staircase. The initial proportion of sig-
nal dots was 50%. The initial staircase step was 4%, which was
halved after the first reversal. All other parameters of the staircase
measurement were the same as described in the Vernier task.
Molecular biological measurements
Peripheral blood was drawn from the cubital vein of the partici-
pants. CGG repeat size was determined using standard Southern
blot analysis as described by Steyaert et al. (2003). FMR1 mRNA
was measured using Affymetrix Quantigene (Vala Sciences Inc.,
CA, USA) based on the protocol of Tassone et al. (2000).
For the quantitative measurement of FMRP levels, we used
the new enzyme-linked immunosorbent assay (ELISA) method
(Iwahashi et al., 2009). The pelleted lymphocytes were suspended
in lysis buffer, MPer (Pierce, Rockford, IL, USA) and protease
inhibitor set III (Calbiochem, San Diego, CA, USA). We used
bicinchoninic acid protein assay kit (Pierce, Rockford, IL, USA) for
the quantification of protein concentration. In order to avoid protein
aggregation, we prepared a maltose binding protein (MBP)-FMRP
fusion. The peptide sequence (KDRNQKKEKPDSVD), which is
located near the carboxy terminus of FMRP, was used for the
production of chicken antibody (AVES Labs, Inc., Tigard, OR,
USA). Well plates were coated with chicken anti-FMRP antibody,
detection antibody, and horseradish peroxidase-conjugated anti-
mouse antibody. Luminescence was read with a Chiron luminom-
eter (Labequip, Markham, Ontario, Canada) (for the details of the
protocol, see Iwahashi et al., 2009).
RESULTS
Visual contrast sensitivity
Fig. 4 presents the contrast sensitivity results. We con-
ducted a group (premutation carriers vs. controls) by stim-
ulus type (M vs. P pathway) repeated measures analysis of
variance (ANOVA), which revealed significant main effects
of group (F(1,39)16.72, P0.001, 0.30), stimulus
type (F(1,39)6.90, P0.05, 0.15), and a two-way in-
eraction between them (F(1,39)14.34, P0.005,
0.27). Tukey honestly significant difference (Tukey
SD) tests revealed that premutation carriers had lower
ontrast sensitivity than controls in the M pathway condi-
ion (P0.001), but not in the P pathway condition (P0.5)
Fig. 4).
ernier threshold
ig. 5 presents the Vernier threshold results. A similar
NOVA was conducted on these results as we used for the
nalysis of contrast sensitivity, but here stimulus type was
tatic vs. motion-defined Vernier. There were significant
ain effects of group (F(1,39)7.90, P0.05, 0.16),
timulus type (F(1,39)14.56, P0.001 m, 0.27), and
two-way interaction between them (F(1,39)6.72,
0.05, 0.15). Tukey HSD tests revealed that premu-
ation carriers displayed higher Vernier thresholds than
ontrols only in the motion-defined condition (P0.05; stat-c: P0.5).
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Fig. 6 depicts the coherence threshold values. As in the
Vernier test, there were significant main effects of group
(F(1,39)4.18, P0.05, 0.10), stimulus type
(F(1,39)13.35, P0.005, 0.25), and a two-way in-
eraction between them (F(1,39)7.27, P0.05,
0.16). Premutation carriers had elevated coherence
hreshold only in the motion condition relative to controls
Tukey HSD, P0.05; form condition: P0.5).
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Fig. 5. Vernier threshold results. Error bars indicate 95% confidence
Tukey HSD tests).Molecular measures and visual psychophysics
FMRP and FMR1 mRNA levels are depicted in Table 1. In
the premutation group, there was a significant positive
correlation between CGG size and FMR1 mRNA level
(Spearman’s R0.82, P0.001), and a tendency between
MR1 mRNA and FMRP levels (R0.38, P0.09). Ta-
ble 2 shows the correlations among FMR1 mRNA/FMRP
evels and visual test measures. In general, both FMR1
RNA and FMRP levels correlated with data from M path-
ay-biased and motion-related tests: higher FMR1 mRNA
Premutation (n=21) 
 Control (n=20)ular
intervals. * P0.001 (comparison of FMR1 premutation carriers and
Premutation (n=21)
 Control (n=20)tion
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efficient visual processing (Table 2).
When a multiple regression analysis was conducted to
etermine the predictors of M pathway-related contrast
ensitivity, FMRP level was significant (b*0.51,
(18)2.55, P0.05), whereas FMR1 mRNA level did not
etain significance (P0.1). In the case of motion-defined
ernier, neither FMRP nor FMR1 mRNA reached the level
f significance (P0.1), whereas in the case of motion
oherence, again, only FMRP was significant (b*0.48,
(18)2.44, P0.05). In accordance with correlation
nalyses, regression analyses did not reveal significant
redictors for P pathway-biased contrast sensitivity, static
ernier, and form coherence threshold (P0.1).
DISCUSSION
In line with results from previous studies (Kéri and
Benedek, 2009, 2010), we found a selective impairment of
visual perceptual functions in FMR1 premutation carriers.
Specifically, contrast sensitivity biasing information pro-
cessing toward the M pathways (precortical mechanisms),
motion-defined Vernier, which assesses the functioning of
the primary visual cortex (V1), and motion coherence were
impaired, whereas all tests related to the P pathways and
its cortical recipients were spared.
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arriers and controls, Tukey HSD tests).
able 2. Correlations between molecular measures and visual functio
Contrast magnocellular Contrast parvocellular V
MR1 0.38 0.1
FMRP 0.58* 0.2 
The table shows Spearman’s correlation coefficients (Rs).
FMR1, fragile X mental retardation mRNA; FMRP, fragile X mental* P0.05.Although visual contrast sensitivity dysfunctions for
gratings with low-spatial and high-temporal frequency
were directly related to the pathology of M cells in the
lateral geniculate nucleus of patients with FXS (Kogan et
al., 2004a), evidence for Vernier stimuli is indirect. It has
been shown, however, that early cortical integration is
critical for Vernier performance (Barlow, 1981; Wilson,
1986; Victor and Conte, 2000; Duncan and Boynton,
2003). The static and motion-defined stimuli used in this
study may distinctly investigate the spatial localization
capacity of form and motion pathways (Regan, 1986;
Banton and Levi, 1993; McKendrick et al., 2006). In our
previous study, FMR1 premutation carriers displayed
elevated Vernier thresholds only for stimuli biasing in-
formation processing toward the M pathways (Kéri and
Benedek, 2009).
According to the concept of the hierarchical organiza-
tion of the visual system, local stimulus attributes pro-
cessed in V1 are integrated in the extrastriate cortex,
including the middle temporal (MT)/V5/V3a and lateral oc-
cipital complex (LOC)/V4 assembling local information into
global motion and form representations, respectively
(Tootell et al., 2003; Orban et al., 2004). At this integrative
stage of information processing, FMR1 premutation carri-
rs again showed a selective deficit for motion stimuli,
Premutation (n=21)
 Controls (n=20)rence
confidence intervals. * P0.05 (comparison of FMR1 premutation
rm Vernier motion Form coherence Motion coherence
0.45* 0.02 0.44*
0.48* 0.06 0.57*
on protein.*
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enedek, 2010).
The critical question of the study was whether these
ysfunctions are related to decreased FMRP or in-
reased FMR1 mRNA levels, a putative toxic gain-of-
unction mechanism of increased expression of ex-
ended CGG repeats (Hagerman et al., 2010). Although
orrelation analysis revealed that both decreased FMRP
nd increased FMR1 mRNA levels were associated with
ess efficient visual processing, regression analyses in-
icated that FMRP was the primary factor. This is highly
eminiscent to that found in the case of amygdala func-
ions in FMR1 permutation carriers, which correlated
ith both FMRP and FMR1 mRNA, but FMRP was the
primary factor (Hessl et al., 2011). A confirmatory aspect
of our study is that, by using a more sensitive method
than the assessment of the number of FMRP positive
lymphocytes, we replicated the relationship between vi-
sual functions and FMRP expression (Kéri and
Benedek, 2011).
Beyond the measurement of FMRP and FMR1 mRNA
levels, there are major differences between our previous
work (Kéri and Benedek, 2009, 2010) and the present one.
First, in this study we investigated male premutation carri-
ers, which is a much straightforward approach because of
the presence of a single X chromosome in these individu-
als (female carriers have a functional copy of the gene that
is expressed randomly in 50% of cells). Moreover, from a
clinical point of view, male premutation carriers are at a
higher risk of RNA toxicity than female premutation carriers
(Hagerman et al., 2010), which warrants the investigation
of potential toxicity markers (e.g. visual dysfunctions). Fi-
nally, we used a psychometrically improved stimulus set,
that is, motion- and form-defined Glass patterns, which
allow a more exact investigation of visual information
processing.
The results of the present study may have an impact on
the differentiation of neurodevelopmental vs. neurodegenera-
tive aspects of fragile X premutation-related diseases. In-
creased FMR1 mRNA is a risk factor for late-onset neurode-
generative processes in premutation carriers, leading to
fragile X-associated tremor/ataxia syndrome. In contrast, de-
creased FMRP may represent the neurodevelopmental as-
pect of the disease (Hagerman and Hagerman, 2004; Rous-
seau et al., 2011). Future longitudinal studies should clarify
whether visual dysfunctions are associated with neurodevel-
opmental changes or with neurodegeneration, although the
primacy of FMRP over FMR1 mRNA supports the neurode-
velopmental hypothesis.
The present study has several limitations. First, behav-
ioral measures were correlated with peripheral markers
from the blood, and no functional brain imaging was used
during the tasks. Nevertheless, the consistent and uniform
pattern of results across different tests is against the like-
lihood of chance findings. FMRP expression has been
documented in the M layers of the lateral geniculate nu-
cleus (Kogan et al., 2004a; Zangenehpour et al., 2009),
which is an indirect support for our findings. Second, al-
though statistical effect size values reflected adequatepower, the sample size was relatively small. Therefore,
future studies must confirm the results in an independent
group of FMR1 premutation carriers.
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